Coherus Oncology
CHRS
188 hedge funds and large institutions have $1.31B invested in Coherus Oncology in 2019 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 69 increasing their positions, 49 reducing their positions, and 18 closing their positions.
156% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 18
87% more call options, than puts
Call options by funds: $8.76M | Put options by funds: $4.67M
41% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 49
13% more funds holding
Funds holding: 167 → 188 (+21)
4.25% more ownership
Funds ownership: 99.43% → 103.68% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less capital invested
Capital invested by funds: $1.41B → $1.31B (-$96.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$29.9M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$16.1M |
| 3 |
Temasek Holdings
Singapore
|
+$15.2M |
| 4 |
D.E. Shaw & Co
New York
|
+$13.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$79.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.8M |
| 3 |
DM
Deerfield Management
New York
|
-$31.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$7.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PHK
201
Point72 Hong Kong
Hong Kong
| – | -$4K | -199 | Closed |
|
|
PWMG
202
Prestige Wealth Management Group
Flemington,
New Jersey
| – | -$3K | -129 | Closed |
|
203
Rockefeller Capital Management
New York
| – | +$74 | +4 | New |
|
204
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$111 | +6 | New |
|
CHRS Hedge Fund Activity: Q4 2019 in Review
188 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2019, worth a combined $1.31B — down 6.8% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new CHRS positions and 18 closed out — a net gain of 28 holders — while 69 added to existing stakes and 49 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $29.9M. The largest seller was Wellington Management Group, cutting an estimated $79.1M.
- 188 institutional investors held Coherus Oncology (CHRS) as of Q4 2019, up from 167 in Q3 2019.
- Funds reported $1.31B of Coherus Oncology stock for Q4 2019, down 6.8% quarter-over-quarter.
- 46 funds opened new Coherus Oncology positions in Q4 2019 and 18 closed out, a net change of +28 holders.
- The largest Coherus Oncology buyer in Q4 2019 was AllianceBernstein, an estimated $29.9M added.
- The largest Coherus Oncology seller in Q4 2019 was Wellington Management Group, an estimated $79.1M sold.
Based on aggregated 13F filings for Q4 2019.